329 related articles for article (PubMed ID: 16782766)
1. In vitro and in vivo CYP3A64 induction and inhibition studies in rhesus monkeys: a preclinical approach for CYP3A-mediated drug interaction studies.
Prueksaritanont T; Kuo Y; Tang C; Li C; Qiu Y; Lu B; Strong-Basalyga K; Richards K; Carr B; Lin JH
Drug Metab Dispos; 2006 Sep; 34(9):1546-55. PubMed ID: 16782766
[TBL] [Abstract][Full Text] [Related]
2. Rifampin induces the in vitro oxidative metabolism, but not the in vivo clearance of diclofenac in rhesus monkeys.
Prueksaritanont T; Li C; Tang C; Kuo Y; Strong-Basalyga K; Carr B
Drug Metab Dispos; 2006 Nov; 34(11):1806-10. PubMed ID: 16928785
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of cynomolgus monkey pregnane X receptor, primary hepatocyte, and in vivo pharmacokinetic changes in predicting human CYP3A4 induction.
Kim S; Dinchuk JE; Anthony MN; Orcutt T; Zoeckler ME; Sauer MB; Mosure KW; Vuppugalla R; Grace JE; Simmermacher J; Dulac HA; Pizzano J; Sinz M
Drug Metab Dispos; 2010 Jan; 38(1):16-24. PubMed ID: 19833845
[TBL] [Abstract][Full Text] [Related]
4. Prediction of crizotinib-midazolam interaction using the Simcyp population-based simulator: comparison of CYP3A time-dependent inhibition between human liver microsomes versus hepatocytes.
Mao J; Johnson TR; Shen Z; Yamazaki S
Drug Metab Dispos; 2013 Feb; 41(2):343-52. PubMed ID: 23129213
[TBL] [Abstract][Full Text] [Related]
5. In vitro assessment of metabolic drug-drug interaction potential of apixaban through cytochrome P450 phenotyping, inhibition, and induction studies.
Wang L; Zhang D; Raghavan N; Yao M; Ma L; Frost CE; Maxwell BD; Chen SY; He K; Goosen TC; Humphreys WG; Grossman SJ
Drug Metab Dispos; 2010 Mar; 38(3):448-58. PubMed ID: 19940026
[TBL] [Abstract][Full Text] [Related]
6. Expression of the human CYP3A4 gene in the small intestine of transgenic mice: in vitro metabolism and pharmacokinetics of midazolam.
Granvil CP; Yu AM; Elizondo G; Akiyama TE; Cheung C; Feigenbaum L; Krausz KW; Gonzalez FJ
Drug Metab Dispos; 2003 May; 31(5):548-58. PubMed ID: 12695342
[TBL] [Abstract][Full Text] [Related]
7. Selective inhibition of human cytochrome P450 3A4 by N-[2(R)-hydroxy-1(S)-indanyl]-5-[2(S)-(1, 1-dimethylethylaminocarbonyl)-4-[(furo[2, 3-b]pyridin-5-yl)methyl]piperazin-1-yl]-4(S)-hydroxy-2(R)-phenylmethy lpentanamide and P-glycoprotein by valspodar in gene transfectant systems.
Kawahara I; Kato Y; Suzuki H; Achira M; Ito K; Crespi CL; Sugiyama Y
Drug Metab Dispos; 2000 Oct; 28(10):1238-43. PubMed ID: 10997946
[TBL] [Abstract][Full Text] [Related]
8. Delineation of the interactions between the chemotherapeutic agent eribulin mesylate (E7389) and human CYP3A4.
Zhang ZY; King BM; Pelletier RD; Wong YN
Cancer Chemother Pharmacol; 2008 Sep; 62(4):707-16. PubMed ID: 18431572
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of P450 inhibition and induction by artemisinin antimalarials in human liver microsomes and primary human hepatocytes.
Xing J; Kirby BJ; Whittington D; Wan Y; Goodlett DR
Drug Metab Dispos; 2012 Sep; 40(9):1757-64. PubMed ID: 22679214
[TBL] [Abstract][Full Text] [Related]
10. Semiphysiologically based pharmacokinetic models for the inhibition of midazolam clearance by diltiazem and its major metabolite.
Zhang X; Quinney SK; Gorski JC; Jones DR; Hall SD
Drug Metab Dispos; 2009 Aug; 37(8):1587-97. PubMed ID: 19420129
[TBL] [Abstract][Full Text] [Related]
11. Contribution of the N-glucuronidation pathway to the overall in vitro metabolic clearance of midazolam in humans.
Klieber S; Hugla S; Ngo R; Arabeyre-Fabre C; Meunier V; Sadoun F; Fedeli O; Rival M; Bourrie M; Guillou F; Maurel P; Fabre G
Drug Metab Dispos; 2008 May; 36(5):851-62. PubMed ID: 18256203
[TBL] [Abstract][Full Text] [Related]
12. Temporal kinetics and concentration-response relationships for induction of CYP1A, CYP2B, and CYP3A in primary cultures of beagle dog hepatocytes.
Graham RA; Tyler LO; Krol WL; Silver IS; Webster LO; Clark P; Chen L; Banks T; LeCluyse EL
J Biochem Mol Toxicol; 2006; 20(2):69-78. PubMed ID: 16615094
[TBL] [Abstract][Full Text] [Related]
13. Characterization of the rhesus monkey CYP3A64 enzyme: species comparisons of CYP3A substrate specificity and kinetics using baculovirus-expressed recombinant enzymes.
Carr B; Norcross R; Fang Y; Lu P; Rodrigues AD; Shou M; Rushmore T; Booth-Genthe C
Drug Metab Dispos; 2006 Oct; 34(10):1703-12. PubMed ID: 16815964
[TBL] [Abstract][Full Text] [Related]
14. Inhibition and kinetics of cytochrome P4503A activity in microsomes from rat, human, and cdna-expressed human cytochrome P450.
Ghosal A; Satoh H; Thomas PE; Bush E; Moore D
Drug Metab Dispos; 1996 Sep; 24(9):940-7. PubMed ID: 8886602
[TBL] [Abstract][Full Text] [Related]
15. Avasimibe induces CYP3A4 and multiple drug resistance protein 1 gene expression through activation of the pregnane X receptor.
Sahi J; Milad MA; Zheng X; Rose KA; Wang H; Stilgenbauer L; Gilbert D; Jolley S; Stern RH; LeCluyse EL
J Pharmacol Exp Ther; 2003 Sep; 306(3):1027-34. PubMed ID: 12766253
[TBL] [Abstract][Full Text] [Related]
16. Prediction of midazolam-CYP3A inhibitors interaction in the human liver from in vivo/in vitro absorption, distribution, and metabolism data.
Yamano K; Yamamoto K; Katashima M; Kotaki H; Takedomi S; Matsuo H; Ohtani H; Sawada Y; Iga T
Drug Metab Dispos; 2001 Apr; 29(4 Pt 1):443-52. PubMed ID: 11259329
[TBL] [Abstract][Full Text] [Related]
17. Primary human hepatocytes as a tool for the evaluation of structure-activity relationship in cytochrome P450 induction potential of xenobiotics: evaluation of rifampin, rifapentine and rifabutin.
Li AP; Reith MK; Rasmussen A; Gorski JC; Hall SD; Xu L; Kaminski DL; Cheng LK
Chem Biol Interact; 1997 Nov; 107(1-2):17-30. PubMed ID: 9402947
[TBL] [Abstract][Full Text] [Related]
18. Complex drug interactions of HIV protease inhibitors 1: inactivation, induction, and inhibition of cytochrome P450 3A by ritonavir or nelfinavir.
Kirby BJ; Collier AC; Kharasch ED; Whittington D; Thummel KE; Unadkat JD
Drug Metab Dispos; 2011 Jun; 39(6):1070-8. PubMed ID: 21406602
[TBL] [Abstract][Full Text] [Related]
19. Applications of primary human hepatocytes in the evaluation of pharmacokinetic drug-drug interactions: evaluation of model drugs terfenadine and rifampin.
Li AP; Jurima-Romet M
Cell Biol Toxicol; 1997 Jul; 13(4-5):365-74. PubMed ID: 9298257
[TBL] [Abstract][Full Text] [Related]
20. Intravenous and oral alfentanil as in vivo probes for hepatic and first-pass cytochrome P450 3A activity: noninvasive assessment by use of pupillary miosis.
Kharasch ED; Walker A; Hoffer C; Sheffels P
Clin Pharmacol Ther; 2004 Nov; 76(5):452-66. PubMed ID: 15536460
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
